Chiesi Farmaceutici S.p.A.

Executive Summary

Chiesi Farmaceutici S.p.A. (the "Chiesi Group" or "Chiesi") is a privately held, family-owned, research-oriented international biopharmaceutical company headquartered in Parma, Italy. Founded in 1935 by Giacomo Chiesi, the company has evolved over nine decades from a small Italian pharmaceutical laboratory into a global biopharmaceutical group ranked 44th among the world's largest pharmaceutical companies by revenue ^[1][2].

Strategic Position

Chiesi operates across three core business franchises:

1. Air Franchise (Respiratory): €1,832M (54% of revenue) — the core engine
2. Care Franchise (Neonatology/Specialty): €818M (24% of revenue)
3. Global Rare Diseases: €763M (22% of revenue; +41% CER) — the fastest-growing segment

The company has delivered three consecutive years of double-digit growth (2022-2024), driven by a diversified product portfolio, geographic expansion (particularly in the U.S.), and the transformative acquisition of Amryt Pharma in 2023.

Medium-Term Targets

CEO Giuseppe Accogli has articulated a five-year growth ambition: mid- to high-single digit sales growth through approximately 2029. Key growth enablers include:

• A 43-project R&D pipeline
• Phase III clinical programs for U.S. market entry of respiratory products (including Trimbow NDA accepted by FDA in October 2025)
• Continued rare diseases portfolio expansion via acquisitions and partnerships
• Carbon-Minimal Inhaler (CMI) transition program with first regulatory submission in December 2025
• Manufacturing investments: €380M Biotech Center of Excellence in Parma (opened September 2024) and €430M Nerviano production site (2025-2030)

For 2025, Chiesi targets "mid-single digit" revenue growth, "strong cash flow generation," and "a solid financial position." H1 2025 results (€1.86B, +13.2% CER) suggest the company is tracking ahead of this guidance.

1. Company History

Founding and Early Years (1935-1970s)

Chiesi Farmaceutici was founded in 1935 by Giacomo Chiesi in Parma, Italy, as a pharmaceutical research laboratory. The company initially focused on developing and manufacturing pharmaceutical products for the Italian domestic market.

Second Generation: Growth and Internationalization (1970s-2000s)

Alberto Chiesi, son of the founder, led the company through significant growth and international expansion:

• Expanded beyond Italy into major European markets
• Developed Curosurf (poractant alfa), the global standard of care for neonatal RDS
• Built a strong franchise in respiratory medicine with products like Clenil and Fostair
• Established commercial affiliates across Europe, the Americas, and Asia

Third Generation: Transformation Era (2000s-Present)

The third generation, including Alessandro Chiesi (Chairman), Maria Paola Chiesi (Vice Chair), and Giacomo Chiesi (EVP Global Rare Diseases), has driven the company's transformation into a diversified biopharmaceutical group.

2. Ownership Structure

Family Ownership

Chiesi Farmaceutici S.p.A. is 100% owned by Valline S.r.l., the family holding company. There are no private equity investors, institutional shareholders, or external minority owners. The company has remained privately held since 1935. Share capital: €75,000,000.

3. Leadership / C-Suite

Chief Executive Officer

Giuseppe Accogli — Group CEO (since April 3, 2023). 25+ years in med-tech and pharma. Previously SVP and COO at Baxter, on Baxter's Executive Committee. Education: University of Bari (economics), SAA Turin and University of San Diego (master's degrees).

Chief Financial Officer

Jean-Marc Bellemin — EVP and Group CFO (since July 2025). Previously CFO at Iovance Biotherapeutics, EVP/CFO at Gritstone Oncology, SVP/CFO at Actelion. Education: Harvard Business School, ESSEC Business School.

Group Executive Leadership Team

4. Drug Portfolio

Air Franchise (Respiratory) — FY2024 Revenue: €1,832M (54%)

Global Rare Diseases — FY2024 Revenue: €763M (22%)

Care Franchise — FY2024 Revenue: €818M (24%)

Trimbow — Growth Star

Trimbow is the world's first single-inhaler triple therapy combining ICS, LABA, and LAMA in an extrafine formulation. It grew 35% YoY in 2024 and is commercialized in nearly 50 countries outside the U.S. FDA NDA acceptance (October 2025) with a decision expected late 2026 makes the U.S. launch a transformative catalyst.

Elfabrio — Rare Disease Cornerstone

PEGylated ERT for Fabry disease with extended half-life (~79 hours). Competes with Sanofi's Fabrazyme and Takeda's Replagal in the ~$2-3B global Fabry ERT market. CHMP positive opinion for 4-week dosing (January 2026) could improve competitiveness.

5. Top 5 CEO Focus Drugs

6. P&L Owners

Chiesi operates a matrix organization where franchise heads own global therapeutic area strategy and product P&L, while regional heads own in-market commercial P&L.

7. R&D Pipeline

Chiesi maintains 43 active projects with R&D investment of €829M (24.3% of revenues), ranking it #1 in Italy and #11 in Europe for pharmaceutical R&D investments.

R&D Infrastructure

• 7 R&D hubs: Parma (Italy, HQ), France, USA, Canada, China, UK, Sweden
• Biotech Center of Excellence (Parma): €380M investment; 105 staff; biologics from cell culture to packaging
• 33 new patent applications filed with EPO in 2024

8. Top Geographies

H1 2025 Regional Performance

• USA: +26%; now ~23% of total sales; driven by rare diseases launches
• EU: +5%; driven by Air franchise
• Overall: €1.86B total, +13.2% CER

Manufacturing Footprint

9. Competitive Landscape

Respiratory (Air Franchise)

Rare Diseases

10. Risks and Challenges

11. Outlook and Valuation Context

Growth Pillars

1. Trimbow U.S. launch (expected 2027): Single largest near-term catalyst; U.S. asthma market is massive
2. Rare diseases expansion: Arbor gene editing ($2B biobucks), Aliada BBB platform, Elfabrio/Filsuvez growth
3. Geographic mix shift: U.S. revenue from small base to 20% with potential for 25-30%; higher pricing supports margins
4. CMI transition: Competitive moat as EU regulations penalize high-GWP propellants

Estimated Valuation (Peer Multiples)

Estimated Enterprise Value Range: €12-16 billion

Peer Comparison

Financial Strength

Chiesi's net cash position of €535M provides significant firepower for further acquisitions (demonstrated appetite up to $1.5B), continued R&D at 24%+ of revenue, and €800M+ committed manufacturing expansion.

12. Patent/Exclusivity Summary

References